Ikarian Capital, LLC Rapt Therapeutics, Inc. Call Options Transaction History

Ikarian Capital, LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$2.89 - $9.38 $246,228 - $799,176	-85,200 Reduced 97.71%	2,000 $6,000
Q1 2024 May 15, 2024	BUY	$6.87 - $26.45 $599,064 - $2.31 Million	87,200 New	87,200 $783,000
Q1 2021 May 17, 2021	BUY	$16.0 - $24.46 $3.94 Million - $6.03 Million	246,500 Added 7042.86%	250,000 $5.55 Million
Q4 2020 Feb 12, 2021	SELL	$15.89 - $40.87 $28,602 - $73,566	-1,800 Reduced 33.96%	3,500 $69,000
Q3 2020 Nov 16, 2020	BUY	$21.6 - $37.5 $114,480 - $198,750	5,300 New	5,300 $170,000

105

49.4M

26.7K

2.4K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $35M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.